drugset
Drugs / CKD-383
last change Nov 2025 re-read 9 days ago

CKD-383

Investigated by
Chong Kun Dang Pharmaceutical · Bumin Hospital

Trials 9

today NCT07304726 · Ph 1 NCT07304700 · Ph 1 NCT07304687 · Ph 1 NCT06695572 · Ph 1 NCT06695598 · Ph 1 NCT06483243 · Ph 1 NCT05897216 · Ph 1 NCT05816759 · Ph 1 NCT04810676 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07304726 Oct → Nov 2025 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT07304700 Oct → Nov 2025 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT07304687 Oct → Nov 2025 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT06695572 Nov → Dec 2024 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT06695598 Nov → Dec 2024 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT06483243 Apr 2024 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05897216 Jul 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05816759 May → Jun 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04810676 Apr → May 2021 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as CKD-383 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05897216 ↗
8

NCT07304726 ↗

NCT05816759 ↗

NCT06483243 ↗

NCT06695572 ↗

NCT07304700 ↗

NCT04810676 ↗

NCT07304687 ↗

NCT06695598 ↗
Route Oral “Peroid 2: CKD-383- PO” NCT04810676 ↗